Stellar work Mason.
The arguments for Bisantrene not only being First-In-Class but also Best-In-Class are brilliant.
Your commitment to detailed research is incredible, but I think what I like the most about this post is just how well structured it is. Words can't describe my appreciation for RAC contributors such as yourself who provide analysis on this level.
I'll have to second @mcmurraj and request you compile this in a PDF. When trying to explain Bisantrene's clinical potential to others - this is the research I want to give to them.
Stellar work Mason.The arguments for Bisantrene not only being...
-
- There are more pages in this discussion • 375 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.040(3.38%) |
Mkt cap ! $198.9M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.13 | $132.0K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2390 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 4805 | 1 |
View Market Depth
| Last trade - 15.57pm 04/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |